葛兰素史克加入MD Anderson癌症免疫疗法研究同盟
关键词: 葛兰素史克 MD Anderson 癌症免疫疗法
2014年4月10日讯 /生物谷BIOON/ --一直以来药物研发市场的竞争都十分激烈,尤其是癌症药物研发的竞争更是趋于白热化。近年来随着癌症免疫疗法的兴起,许多医药巨头都纷纷投身其中希望分一杯羹。而MD安德森癌症研究中心牵头的moon shots计划就是希望联合其他医药巨头合作进行癌症免疫疗法的开发。最近moon shots计划迎来了其有一个重量级参与者--葛兰素史克龙8游戏手机登录。葛兰素史克、阿斯利康、辉瑞、强生和安德森癌症研究中心将合作开发anti-CTLA-4类免疫药物以对抗并赶超目前在该领域领先的默沙东、罗氏和施贵宝三家龙8游戏手机登录。这三家医药龙8游戏手机登录分别有自己的PD-1和PD-L1抗癌药物。默沙东的加入使得目前世界上最为强大的几家生物医药龙8游戏手机登录研发力量汇集在一起,这一"黄金搭档"未来能为癌症药物研发领域带来何种变化,让龙8游戏手机登录拭目以待。(生物谷Bioon.com)
详细英文报道:
Drug research is a small world, where the main players often intersect repeatedly as they take on new roles at different institutions. And MD Anderson's new "moon shots" program on immuno-oncology is proving that maxim yet again as GlaxoSmithKline's immunotherapy team suits up for the last big slot in an ambitious alliance of industry giants aimed at discovering some new products in the red-hot cancer R&D field.
GlaxoSmithKline ($GSK) is taking a berth next to teams from AstraZeneca ($AZN), Pfizer ($PFE) and Johnson & Johnson ($J&J). And the pact brings together two of the key players in the development of Yervoy, the pioneering anti-CTLA-4 immune checkpoint inhibitor which helped trigger one of the most frenetic development races the industry has seen.
Axel Hoos, GSK's chief of immuno-oncology, was the medical lead for that sector at Bristol-Myers Squibb ($BMY), which developed Yervoy. And Jim Allison, who's in charge of the moon shot program at MD Anderson, did the original research that gave birth to the therapy at the University of California, Berkeley.
It's no surprise that GSK's team will work in a collaboration that has attracted Pfizer, J&J and AstraZeneca's biologics arm MedImmune. They're all playing catch-up with the leaders in this race: Bristol-Myers Squibb, Merck ($MRK) and Roche ($RHHBY), which are working on the front-running PD-1 and PD-L1 programs in the clinic. The outsiders want to narrow the gap as quickly as possible. Of the four, AstraZeneca is occasionally mentioned as a contender, with an early-stage immunotherapy program with potential. Now they'll all be looking for second-wave programs that can be moved swiftly into clinical development efforts.
Their work will build "upon the early successes of immunotherapy by extending this approach to many types of cancer and exploring ways to improve treatment effectiveness," said Allison in a statement.
From the moment MD Anderson, one of the premier cancer treatment centers in the country, wooed Allison with a $40 million campaign to build this coalition, the principals wanted to limit the number of seats at the table. That proved a smart tactic, spurring some of the world's largest R&D operations to grab a chair while they were still available. MD Anderson says they'll also be working with start-up biotechs interested in developing their own immunotherapies.
But the star team is complete.